Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on IDT Australia.
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot
Health & Biotech
ASX Health Winners: Biotechs up 10pc in November, and Janus Henderson’s prediction for 2024
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
News
In Case You Missed It: A strategic superannuation partnership takes the lead today
Health & Biotech
ASX Health Stocks: IDT on strong growth trajectory, Paradigm smashed 30pc on cap raise
News
Top 10 at 10: WA1 scales new heights, REZ hits a shallow nickel orebody in the making
Health & Biotech
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Health & Biotech
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
Health & Biotech
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
News
CLOSING BELL: Aussies find a cost of living crisis fix, by stealing everything not nailed down
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
Health & Biotech
ASX Health Stocks: Patrys wins fresh grant, IDT does not and Next Science is off to sell stuff in Canada
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
Health & Biotech